Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Rockwell Medical, Inc. Price Target Update - Money Flow Index |
 |
 |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 15 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.15. The higher estimate of target price is $26 , while the lower price target estimate is $4 Rockwell Medical, Inc. (NASDAQ:RMTI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2.55 by 6 Wall Street Analysts. 3 analysts have added the shares in their list of strong buys. 1 analysts have advised hold. 2 has rated the company as strong sell. Several analysts have commented on the company rating. In a research note released to the investors, Morgan Stanley initiates coverage on its rating on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Underweight on the shares. In a recent information released to the investors, Morgan Stanley announces the price target of $7 per share. The rating by the firm was issued on August 13, 2015. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Thursday session in red amid volatile trading. The shares closed down 0.64 points or 5.47% at $11.05 with 1,082,747 shares getting traded. Post opening the session at $11.51, the shares hit an intraday low of $10.961 and an intraday high of $11.99 and the price vacillated in this range throughout the day. The company has a market cap of $555 million and the number of outstanding shares have been calculated to be 50,223,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $18.8999 and the 52-week low is $8.095. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc. has lost 4.25% in the last five trading days and dropped 33.95% in the last 4 weeks. Rockwell Medical, Inc. is up 7.18% in the last 3-month period. Year-to-Date the stock performance stands at 7.49%. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
